Back to homepage

Infectious disease

Urinary tract infections in the elderly: a review of disease characteristics and current treatment options

Authors: Leocadio Rodriguez-Mañas MD, PhD

This narrative review considers the characteristics of urinary tract infections – prevalence and incidence, disease burden, risk factors, and clinical presentation – in the elderly, and examines current treatment options to manage urinary tract infections in the community.

More

Coronavirus disease 2019 (COVID-19): latest developments in potential treatments

Authors: Kam Lun Hon MBBS, MD, Karen Ka Yan Leung MBBS, MRCPCH, Alexander KC Leung MBBS, FRCPC, FRCP (UK & Irel), FRCPCH, FAAP, Su Yun Qian MD, Vivian PY Chan MPharm, MSc (Clin Pharm), BPharm, BCPPS, BCNSP, Patrick Ip MBBS, FRCPCH (Hon), FRCPCH, Ian CK Wong BPharm (Hons), MSc, PhD, FRCPCH (Hon)

This overview aims to review the current developments in preventive treatments and therapies for COVID-19.

More

Can vitamins and/or supplements provide hope against coronavirus?

Authors: Sarah M Michienzi PharmD, Melissa E Badowski PharmD

The goal of this narrative review is to evaluate current and ongoing clinical trials of vitamins and supplements, alone or in combination with each other or other therapies, for the treatment of COVID-19.

More

Neurological features of COVID-19 and their treatment: a review

Authors: Daniele Orsucci MD, Elena Caldarazzo Ienco MD, Gianpaolo Nocita MD, Alessandro Napolitano MD, Marco Vista MD

This review aims to summarize early findings on
the neurological features of COVID-19 and their treatment
approaches.

More

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic

Authors: Matteo Bassetti MD, PhD, Paolo Pelosi MD, FERS, Chiara Robba MD, PhD, Antonio Vena MD, PhD, Daniele Roberto Giacobbe MD

Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.

More